Please use this identifier to cite or link to this item:
|Title||Brain Natriuretic Peptide (BNP) among Congestive Heart Failure (CHF) Patients in Gaza Strip – Palestine|
Brain natriuretic peptide (BNP) has been established as a new and reliable laboratory marker for congestive heart failure (CHF). BNP is a neurohormone secreted by the cardiac ventricles in response to volume expansion and pressure overload. This study aimed to examine the utility of BNP for diagnosing heart failure, and to evaluate the hypertensive patients who are at high risk of progressive ventricular hypertrophy and remodeling heart failure or death. Retrospective design (case–control study) was used to collect data from 75 patients with CHF and history of hypertension (case group), and 75 patients with history of hypertension only (control group). CHF subjects consisted of 22 subjects with acute heart failure, and 53 subjects with chronic heart failure. CHF group was further classified into four classes, the diagnosis and classification of CHF were done according to the New York Heart Association (NYHA) by two cardiologists. Self report structure interview and blood samples were obtained from both groups. Abbott AxSYM in conjunction with a recently available immunoassay kit for BNP hormone Microparticle Enzyme Immunoassay (MEIA) system was used for measurement of BNP. Chi square, t-test, Kruskal-Wallis and ANOVA-I were used to analyze data. The results of the study showed a significant relationship between BNP hormone and CHF (P value = 0.00). The obtained data suggest that the measurement of BNP levels may be helpful in the diagnosis and prognosis of CHF and in selecting patients for further evaluation. To the best of our knowledge this is the first study inPalestine, investigating the role of BNP in CHF and HTN subjects, taking into consideration the socio-economic factors.
|Publisher||الجامعة الإسلامية - غزة|
|Files in this item|